中国实用内科杂志2024，Vol.44Issue(10)：861-865,5.DOI:10.19538/j.nk2024100113
PI3K抑制剂联合阿扎胞苷治疗复发/难治血管免疫母细胞性T细胞淋巴瘤5例研究
PI3K inhibitor combined with azacitidine for relapsed/refractory angioimmunoblastic T-cell lymphoma:a study of 5 cases
摘要
Abstract
Objective To investigate the efficacy and safety of PI3K inhibitors combined with azacitidine in the treatment of relapsed/refractory angioimmunoblastic T cell lymphoma(r/r AITL).Methods A retrospective analysis of the efficacy and safety of 5 r/r AITL patients treated by PI3K inhibitor combined with azacitidine in the Department of Hematology,the First Affiliated Hospital of Soochow University from March 2023 to November 2023.Results There were 3 male and 2 female among the five patients,with a median age of 58(range 50-86)years at diagnosis.All patients Ann Arbor stages were Ⅲ-Ⅳ,including three with bone marrow involvement,two experiencing relapsepost-autologous hematopoietic stem cell transplantation and three with EB virus infection.One or more gene mutations such as RHOA,IDH2,TET2,DNMT3A and EP300 were detected by Next-Generation Sequencing(NGS)in 4 patients.All five patients achieved remission,with 2 achieving complete response(CR)and 3achieving partial response(PR).The median follow-up was 286(153-397)days,andmedian progression free survival(PFS)and overall survival(OS)werenot reached.Adverse events were primarily grade 1-2,which were effectively controlled after supportive treatment,and no severe fatal adverse reactions occurred.Conclusion The patients with r/r AITL lacked effective rescue treatment options and had a poor prognosis,the PI3K inhibitor combined with azacitidine regimen successfully rescued five cases of r/r AITL with few adverse reactions and good tolerability,which is worthy of further promotion and application.关键词
PI3K抑制剂/阿扎胞苷/复发/难治血管免疫母细胞性T细胞淋巴瘤/疗效/安全性Key words
PI3K inhibitor/Azacitidine/relapsed/refractory angioimmunoblastic T-cell lymphoma/efficacy/safety分类
医药卫生引用本文复制引用
杨琴,李彩霞,李嘉琦,耿洪智,曾良玉,张莹,马朝霞,宗香萍,蔡文治,吴德沛..PI3K抑制剂联合阿扎胞苷治疗复发/难治血管免疫母细胞性T细胞淋巴瘤5例研究[J].中国实用内科杂志,2024,44(10):861-865,5.基金项目
国家重点研发计划(2022YFC2502700) （2022YFC2502700）
国家自然科学基金(82020108003) （82020108003）
